With an impressive $12.4 billion invested across 719 deals, this period defied expectations of a prolonged funding winter and showcased remarkable growth. These deals span a wide range of digital health subsectors, from AI and LLMs to health information management and connected medical diagnostics. The industry saw a significant surge in momentum in Q2 2024, outperforming Q1 with $7.1 billion in funding compared to $5.3 billion.

Key areas such as AI, LLMs, health information management, connected medical diagnostics, and research solutions (i.e., TechBio) have emerged as focal points for VC and corporate incubators, accelerators, and equity funds, so critical to providing the financial and strategic support necessary to jump-start early-stage companies. A steady stream of M&A activity and strategic partnerships indicate ongoing global digital health market consolidation.

Galen Growth has been tracking every detail and deal and analyzing the digital health sector’s ups and downs, and it has now returned to the forefront of the C-Suite. To arrive at its analyses, Galen Growth tracks some 500 million data points across 30,000 sector players. Medika Life was able to preview some of the data to provide these highlights. Our assumption all along is that the spike in COVID-era investment was pure enthusiasm absent due diligence and that the category would rebound. This report confirms that hypothesis.

Medika Life readers can access the H1 2024 report here:

https://www.healthtechalpha.com/research/h1-2024-digital-health-global-key-trends-report

H1 2024 Growth

The $ 12.4 billion investment in the first half (H1) of 2024 is a significant milestone, marking a 5% increase compared to last year’s H1 2023. This robust performance challenges the narrative of a funding winter, showcasing sustained investor confidence. Q2 outpaced Q1 significantly, with a 34% increase in funding, indicating growing momentum.

“Anyone who thought digital health growth is stagnant was proven wrong by this recent finding data.  Investors find the value in these innovations – the challenge that remains is about the culture of the health sector – the role of the health care community in embracing these technologies,” reflects WebMD Chief Medical Officer John Whyte, MD, MPH, who has been a national voice on the potential of smart medical devices to improve people’s care.

More than 1,600 investors participated in H1 2024, with 50 making more than three investments, up from 47 in the previous year. This suggests a renewed confidence and a growing core of committed digital health investors. Key indicators such as the high number of mega deals and the significant proportion of funding directed towards AI-enabled companies underscore this trend.

Key Trends and Insights

Generative AI and AI- and LLM-enabled companies continue to gain investor attention, particularly in health information management. Despite comprising only 40% of the venture ecosystem, AI-enabled companies received 56% of the venture capital in the sector. This trend highlights the critical role of AI in driving innovation and attracting significant investment in healthcare.

“I believe that AI and large language models represent a new and unique level of revitalization for digital health.  The utility and functionality of many digital health devices can be transformed through artificial intelligence and large language models (LLMs). It’s this fundamental transformation that breathes life into what was a lackluster and ‘gadget-based’ initiative,” offers John Nosta, a global innovation thought leader who speaks to the “Age of Cognition” and how it impacts the future of medical care and technology.

The US and North American countries led digital health funding, while Europe remained the second-most funded region. Future reports will provide deeper insights into these trends with a detailed regional breakdown and analysis.

Mega-Deal Investments

Mega deals were crucial in the Digital health funding landscape during H1 2024. The period saw 26 mega deals (deal value ≥ $100 million) totaling $4.9 billion, accounting for 39% of the overall funding. This represents a 9% increase from H1 2023, which recorded 24 mega deals amounting to $4.5 billion. The average mega deal size reached its highest since 2019, at $191 million.

“The significant increase in mega deals and the robust M&A activity in H1 2024 highlight a maturing ecosystem rapidly consolidating and strategically repositioning itself,” said Galen Growth Founder and CEO Julien de Salsberry to Medika Life. “These insights are crucial for stakeholders to understand the evolving dynamics of the market and to make informed decisions that will drive future growth and innovation in the Digital health space.”

Notable Mega Deals:

• Xaira Therapeutics – $1,000 million (ARCH Venture Partners, Foresite Labs)
• Formation Bio – $375 million (Andreessen Horowitz)
• Freenome – $254 million (Roche)
• PharmEasy – $216 million (MEMG)
• Blackrock Neurotech – $214.3 million (Tether)

The geographical distribution of these mega deals highlights continued US dominance in attracting substantial investments. Of the 26 mega deals, 22 were secured by U.S.-founded companies, underscoring this nation’s engaged digital health ecosystem.

US Digital Health Funding by Investment Stage

The distribution of funding across various stages suggests a vibrant investment cadence supporting companies at different growth phases:

• Early-stage deals: 132 deals (32% of all deals)
• Series A: 88 deals
• Series B: 65 deals
• Series C: 42 deals
• Series D & Beyond: 35 deals
• Other Stages: 43 deals across various other stages.

Acquisitions and Sell-Offs

Mergers and acquisitions (M&A) activity in the Digital health sector remained robust in H1 2024, with 96 deals completed, a slight increase of 2% from H1 2023. This steady pace of M&A transactions demonstrates the industry’s ongoing consolidation and strategic repositioning.

• Noteworthy Transactions:
• Altaris Capital Partners acquired and delisted Sharecare for $518 million.
• Roche acquired the LumiraDx point-of-care technology platform for $295 million.
• Click Therapeutics acquired assets from the bankrupt Better Therapeutics.
• LabCorp acquired some assets from Invitae, a genetic testing company.

The elevated activity in M&As and asset acquisitions reflects the dynamic nature of the Digital health sector, with companies adapting to market conditions and consolidating resources.

Partnerships and Collaborations

The Digital health sector witnessed an almost unchanged collaborative environment during the first half of 2024, with 1,730 partnerships recorded, a slight 2% decrease from H1 2023. Healthcare providers emerged as the primary drivers of partnerships, forging 306 collaborations. This underscores the growing integration of digital solutions in traditional healthcare settings.

Newsworthy Collaborations:

• Nvidia – Nine partnerships focusing on health AI applications.
• Medical Diagnostics and Health Management Solutions – Key areas for venture-to-venture partnerships, indicating a trend towards leveraging complementary technologies and expertise.

Regional Funding Snapshots

United States: The U.S. maintained its dominant position, attracting $9.5 billion across 405 deals, up 14% year-over-year. The distribution of funding across various stages reveals a revived and focused ecosystem supporting companies along the growth cycle.

Europe: Despite a 10% decrease in funding to $1.52 billion across 158 deals, Europe remains the second most heavily funded region. The funding landscape showcases diverse investment stages, indicating a healthy and maturing ecosystem.

Asia Pacific: Asia Pacific attracted $1.17 billion across 118 deals, down 7% from H1 2023. Despite the decreased funding, the region remains strong in diagnostic technologies and patient-centric digital solutions.

Overview

The first half of 2024 has demonstrated the resilience and evolution of the digital health sector. With substantial investments and strategic collaborations driving innovation and growth, the $12.4 billion funding across 719 deals underscores renewed investor enthusiasm. The sector’s solid M&A landscape and increasing mega-deal activity convey a maturing ecosystem poised for continued integration into the mainstream health ecosystem.

As digital health ventures in the US, Europe, and Asia Pacific push the boundaries of health innovation, the groundwork laid during H1 2024 suggests a transformative future for the industry. Data from H1 2024 means that the digital health venture C-suite and investors can breathe a sigh of relief as valuations stabilize and deal flow continues.

This outlook calls for careful and informed decisions driven by proof points and facts, steering away from the speculative fervor of the COVID era.   The reflections of Galen Growth’s Julien de Salsberry reinforce that digital health – an expansive innovation field – that warrants payers, providers, and product innovators full attention:

“The Digital health sector’s resilience and sustained growth, as evidenced by the $12.4 billion investment in H1 2024, is a testament to the unwavering confidence of investors in the transformative potential of digital health technologies. This data underscores innovation’s critical role in enhancing healthcare delivery and outcomes globally.”

The post Digital Health Revitalized Returns to the Industry and Investment Sectors’ Priority Dashboard – Updated with Video Exclusive appeared first on Medika Life.

Scott Wiener made a startling revelation at a spring legislative committee hearing: “I was in the hospital. I experienced the most intense abdominal pain that I could even imagine.”

The Democratic state senator recalled crawling up the stairs to his landlord’s apartment last July to get a ride to the hospital.

The San Francisco lawmaker also disclosed to his colleagues on the Senate Health Committee that he has Crohn’s disease, a chronic autoimmune condition that causes inflammation in the digestive tract. His body, he said, wasn’t responding to his medication, which led to abscesses in his abdomen and a weeklong stay in the hospital.

Wiener is a youthful, lean 52-year-old who is known around the Capitol as an energetic workaholic. It’s a reputation he has had since his early days as a San Francisco supervisor.

He is known for his progressive proposals on housing affordability, safe injection sites, mental health, and sentencing reform. Wiener is also an intensely private lawmaker, who, by his own admission, isn’t the type to “personalize these things.”

He opened up after some Republican lawmakers and health insurance lobbyists questioned the cost of one of his bills during a committee hearing in April. SB 853 would require state-regulated insurance companies to cover a denied prescription while the patient appeals the decision if a patient has previously taken the drug — even if it’s at a higher dose than the FDA has approved or in a different form than was previously prescribed.

The clause about drug dosage and form is especially important for patients who have an autoimmune disease, such as Crohn’s, because they sometimes need a higher dose of a medication than the FDA recommends. Or the medicine might work better for them in injectable form than as a pill.

Patients who are denied medicine often go without it while they appeal, a process that health plans say generally takes 30 days. Some patients, however, say it can take months.

Under his bill, if he ever had to contest his health plan’s decisions about his medications, Weiner told his colleagues, “I could get the proper dosage during the appeal so that I wouldn’t have to miss more health committee meetings.”

But Jedd Hampton, legislative affairs director for the California Association of Health Plans, said the bill would give patients “unfettered access to prescription drugs,” which could lead to abuse and addiction. “We are strongly concerned that stripping health plans of the ability to provide clinical oversight and access to certain drugs may cause potentially adverse reactions and real harm to our enrollees,” he said.

The Senate approved Wiener’s bill 39-0 last month. It is awaiting a hearing in the Assembly.

Wiener sat down with KHN senior correspondent Samantha Young to talk about what it’s like to live with Crohn’s disease, his hospital stay, and how that experience informs his work. The interview has been edited for length and clarity.

Q: How does Crohn’s disease affect your life?

I have had it for 33 years, and I’ve been lucky that, other than last year, I just deal with periodic pain. But last spring, I started getting more symptomatic, and I was hospitalized for one night at the end of June with pain. Then a month later, on a Tuesday night, getting into bed, all of a sudden, the only way to describe it, it was like an electrical storm in my abdomen. The most severe pain I have ever felt.

The hospital did a scan and found multiple abscesses in my abdomen. I was in the intensive care unit for three nights and in the hospital for a week. They had to drain abscesses, and I was on heavy antibiotics. I had a reoccurrence in September, and I had to go back to the hospital for four days. But now it got all cleared out, and I’ve been doing great since then. I feel lucky.

It’s never really affected my ability to be a workaholic, my ability to just live my life, travel, vacation. I feel very privileged. There are other people with other autoimmune diseases and Crohn’s who are much more impacted.

Q: How do you monitor your Crohn’s?

After I left the hospital, I began consulting with an infectious disease specialist. I know what to look for, so hopefully this will never happen again. I know I need to go to the hospital if I have an unexplained fever with some pain and I’m testing negative for covid-19. For a lot of people, if you have an unexplained fever for a few days and you just don’t feel well, you let it go. For me, I need to go to the hospital and have a scan done just to make sure I don’t have an infection.

Q: There are so many chronic health conditions that require specialty care and drugs, which can be very expensive. Have you ever had trouble getting coverage for them?

I was always on common generic medicines, but then the two times I had to go on specialty drugs, I’ve had two opposite experiences. The first time, my insurance company said I had to first try and fail the steroid prednisone. Well, anyone who knows anything about prednisone knows that it is a last resort. Prednisone has so many side effects, and long term, it can cause a lot of problems. It was just shocking to me and my doctor that the insurance company said you have to try and fail.

Then, when my doctor went to switch me to what I’m on now, it was approved within 24 hours. It was as easy as could be. So I’ve experienced amazing health plan response and also really challenging response.

Q: What does that tell you as a lawmaker about the way our health care system works?

Sometimes the system works really well, and sometimes it doesn’t. And if you are not the kind of person who can advocate for yourself or you don’t have your primary care physician able to advocate for you, you can really have a bad outcome.

Q: What have you and other lawmakers done to address that?

We do a lot of work around health plan accountability. I’m carrying another bill, SB 858, that would increase fines for health plan violations. During my entire experience last year, with various hospitalizations, my health plan was terrific. Everything was very prompt, and we always had a nurse follow up with me after I left the hospital. But people do fall through the cracks — sometimes mistakes are made in terms of denying coverage.

I’ve supported and co-authored numerous pieces of legislation to lower prescription drug costs. I’m very fortunate that I have excellent health insurance, but a lot of people don’t. I haven’t had copay problems, but there are people who had to pay huge amounts of money just to get medicine because coverage doesn’t kick in until they pay $5,000. It makes me very sensitive to those cost issues. And I was a proud champion and co-author of AB 1400, Assembly member Ash Kalra’s single-payer legislation.

Q: Does your personal life influence the bills you sponsor?

My personal experience certainly influences my perspective on life. My personal experience as a gay man, as a patient, and in the community in general. It’s true for any elected official, and that’s why it’s important to have officials with lots of life experience because I think it makes you a better representative.

Q: Your bill came under tough questioning from some Republican lawmakers, but that shifted after you shared your story. Do you think personal stories like yours carry weight with your colleagues and the public?

Yeah. I was really grateful that it got bipartisan support. And I think for some of these issues, there’s really no reason for it to be partisan.

As elected officials, sometimes we’re viewed as caricatures of human beings. We’re human beings who have the same challenges that other people do — challenges parenting or having a sick family member. We’ve had members who have had to deal with difficult family situations or health situations. I think it’s good for the public to know that.

This story was produced by KHN, which publishes California Healthline, an editorially independent service of the California Health Care Foundation.

The post Lawmaker Takes on Insurance Companies and Gets Personal About His Health appeared first on Medika Life.